Clinical Trials
12 trialsNCT05186753 2026-05-22
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT01384513 2026-04-15
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT00255346 2025-12-30
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04761822 2025-08-12
SARS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT01701843 2025-02-24
Cromoglicate in Mastocytosis
LEO Pharma
Phase 2 Terminated
NCT00831974 2018-12-11
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
AB Science
Phase 2 Completed
NCT01266369 2018-12-10
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
AB Science
Phase 2 Completed
NCT00006413 2017-07-02
Stem Cell Transplantation to Treat Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT02478957 2016-09-29
Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma
Phase 2 Completed
NCT01920204 2015-01-19
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
Phase 2 Unknown